CTLA4 and melanoma: Anti-CTLA-4 antibody (Ipilimumab/Tramelimumab), approved for clinical management of CM more than five years ago [182] and followed closely by the approval of anti-PD1 (Nivolumab) [183], is the main immune therapeutical player that changed the fate of melanoma patients.